These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 2677013)

  • 1. Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety of Medicines.
    J Biol Stand; 1989 Jul; 17(3):203-12. PubMed ID: 2677013
    [No Abstract]   [Full Text] [Related]  

  • 2. Notes to applicants for marketing authorizations on the production and quality control of medicinal products derived by recombinant DNA technology. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.
    J Biol Stand; 1989 Jul; 17(3):223-31. PubMed ID: 2793874
    [No Abstract]   [Full Text] [Related]  

  • 3. Notes to applicants for marketing authorizations on the production and quality control of monoclonal antibodies of murine origin intended for use in man. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.
    Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy
    J Biol Stand; 1989 Jul; 17(3):213-22. PubMed ID: 2793873
    [No Abstract]   [Full Text] [Related]  

  • 4. Note for guidance. Guidelines for medicinal products derived from human blood and plasma. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1992 Jun; 20(2):159-64. PubMed ID: 1389112
    [No Abstract]   [Full Text] [Related]  

  • 5. Note for guidance. Production and quality control of human monoclonal antibodies. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):133-8. PubMed ID: 1888492
    [No Abstract]   [Full Text] [Related]  

  • 6. Note for guidance. Production and quality control of cytokine products derived by biotechnological processes. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):125-31. PubMed ID: 1888491
    [No Abstract]   [Full Text] [Related]  

  • 7. Note for guidance. Guidelines for minimizing the risk of transmitting agents causing spongiform encephalopathy via medicinal products. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1992 Jun; 20(2):155-8. PubMed ID: 1389111
    [No Abstract]   [Full Text] [Related]  

  • 8. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
    [No Abstract]   [Full Text] [Related]  

  • 9. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus validation procedures: practical aspects.
    Minor PD
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S10-2. PubMed ID: 7495959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICH guidelines: inception, revision, and implications for drug development.
    Wang T; Jacobson-Kram D; Pilaro AM; Lapadula D; Jacobs A; Brown P; Lipscomb J; McGuinn WD
    Toxicol Sci; 2010 Dec; 118(2):356-67. PubMed ID: 20861066
    [No Abstract]   [Full Text] [Related]  

  • 13. Genotoxicity testing of biotechnology-derived products. Report of a GUM task force. Gesellschaft für Umweltmutationsforschung.
    Gocke E; Albertini S; Brendler-Schwaab S; Müller L; Suter W; Würgler FE
    Mutat Res; 1999 Mar; 436(2):137-56. PubMed ID: 10095137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of biotechnology products for therapeutic use.
    Sims J
    Toxicol Lett; 2001 Mar; 120(1-3):59-66. PubMed ID: 11323162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive toxicity testing of therapeutic biotechnology agents.
    Henck JW; Hilbish KG; Serabian MA; Cavagnaro JA; Hendrickx AG; Agnish ND; Kung AH; Mordenti J
    Teratology; 1996 Mar; 53(3):185-95. PubMed ID: 8761886
    [No Abstract]   [Full Text] [Related]  

  • 16. Implementing quality by design for biotech products: Are regulators on track?
    Luciani F; Galluzzo S; Gaggioli A; Kruse NA; Venneugues P; Schneider CK; Pini C; Melchiorri D
    MAbs; 2015; 7(3):451-5. PubMed ID: 25853461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical development of biopharmaceuticals.
    Baumann A
    Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical safety assessment: in vitro -- in vivo testing.
    Højelse F
    Pharmacol Toxicol; 2000; 86 Suppl 1():6-7. PubMed ID: 10905745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance.
    Nakazawa T; Kurokawa M; Kimura K; Wakata A; Hisada S; Inoue T; Sagami F; Heidel SM; Kawakami K; Shinoda K; Onodera H; Kumagai Y; Ohno Y; Kawamura N; Yamazaki T; Inoue T
    J Toxicol Sci; 2008 Aug; 33(3):277-82. PubMed ID: 18670158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Points to consider" regarding safety assessment of biotechnology-derived pharmaceuticals in non-clinical studies (English translation).
    Nakazawa T; Kai S; Kawai M; Maki E; Sagami F; Onodera H; Kitajima S; Inoue T
    J Toxicol Sci; 2004 Dec; 29(5):497-504. PubMed ID: 15729005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.